GENFIT S.A. American Depositary Shares
GNFT Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Recent trades of GNFT by members of U.S. Congress
GNFT Stock Insider Trading Activity
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
GNFT Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
GNFT Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by GNFT's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
GNFT Revenue by Segment or Geography
By Segment
By Geography
GNFT Income Statement
GNFT Balance Sheet
GNFT Cash Flow
U.S. Patents
New patents grants
-
Patent Title: Methods of treatment of cholestatic diseases Feb. 25, 2025
-
Patent Title: Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammation Jan. 28, 2025
-
Patent Title: Non-invasive diagnostic of non-alcoholic steatohepatitis Oct. 01, 2024
-
Patent Title: Pharmaceutical compositions for combination therapy Aug. 06, 2024
-
Patent Title: Methods of treatment of cholestatic diseases Aug. 06, 2024
-
Patent Title: Elafibranor salts Jul. 09, 2024
-
Patent Title: Rorgamma modulators and uses thereof May. 07, 2024
-
Patent Title: Methods of treatment of cholestatic diseases Jan. 02, 2024
-
Patent Title: Methods of treatment of cholestatic diseases Dec. 26, 2023
-
Patent Title: Automated pattern recognition and scoring method of histological images Jun. 13, 2023
-
Patent Title: Pharmaceutical compositions for combination therapy Feb. 28, 2023
-
Patent Title: Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis Dec. 06, 2022
-
Patent Title: Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor Nov. 01, 2022
-
Patent Title: Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent Oct. 25, 2022
-
Patent Title: Methods of treatment for cholestatic and fibrotic diseases Aug. 02, 2022
-
Patent Title: Methods for diagnosing and evaluating non-alcoholic steatohepatitis Jun. 28, 2022
-
Patent Title: Methods of treatment of cholestatic diseases May. 17, 2022
-
Patent Title: Pharmaceutical compositions for combination therapy Dec. 07, 2021
-
Patent Title: Methods of treatment of cholestatic diseases Nov. 30, 2021
-
Patent Title: Rorgamma modulators and uses thereof Nov. 02, 2021
-
Patent Title: Methods of treatment for cholestatic and fibrotic diseases Aug. 31, 2021
-
Patent Title: Rorgamma modulators and uses thereof Aug. 03, 2021
-
Patent Title: N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2h-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ror-gamma modulators for treating autoimmune diseases Jul. 06, 2021
-
Patent Title: Pharmaceutical compositions for combination therapy Jun. 15, 2021
-
Patent Title: Rorgamma modulators and uses thereof Apr. 27, 2021
-
Patent Title: Methods of treatment for cholestatic and fibrotic diseases Feb. 02, 2021
-
Patent Title: Derivatives of 6-substituted triazolopyridazines as rev-erb agonists Oct. 13, 2020
-
Patent Title: Methods of treatment of fibrosis and cancers Oct. 06, 2020
-
Patent Title: Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders Jul. 28, 2020
-
Patent Title: Methods of treatment for cholestatic and fibrotic diseases May. 19, 2020
-
Patent Title: Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders Jul. 16, 2019
-
Patent Title: Methods of treatment for cholestatic and fibrotic diseases Nov. 20, 2018
-
Patent Title: Methods of treatment for cholestatic and fibrotic diseases Nov. 20, 2018
-
Patent Title: Methods of treatment for cholestatic and fibrotic diseases Nov. 06, 2018
-
Patent Title: Methods of treatment for cholestatic and fibrotic diseases Nov. 06, 2018
-
Patent Title: Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders Jul. 17, 2018
-
Patent Title: Heterocyclic derivatives as rorgamma modulators Feb. 27, 2018
-
Patent Title: Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders Oct. 10, 2017
-
Patent Title: Derivatives of 6-substituted triazolopyridazines as rev-erb agonists Mar. 07, 2017
-
Patent Title: Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders Mar. 07, 2017
-
Patent Title: Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders Dec. 29, 2015
-
Patent Title: 1,3-diphenylpropane derivatives, preparations and uses thereof Aug. 25, 2015
-
Patent Title: Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders Nov. 25, 2014
-
Patent Title: Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders Jul. 08, 2014
-
Patent Title: Preparation of chalcone derivatives Jul. 01, 2014
-
Patent Title: Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof Jun. 11, 2013
-
Patent Title: Ppar agonist compounds, preparation and uses Jun. 11, 2013
-
Patent Title: Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof Sep. 04, 2012
-
Patent Title: Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof May. 29, 2012
-
Patent Title: Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof Jan. 31, 2012
Government Contracts
Federal grants, loans, and purchases
Government Contracts
Estimated quarterly amount awarded from public contracts
GNFT News
Recent insights relating to GNFT
WallStreetBets
Number of mentions of GNFT in WallStreetBets Daily Discussion
CNBC Recommendations
Recent picks made for GNFT stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in GNFT
GNFT Analyst Ratings
GNFT Stock Forecasts
...
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
GNFT Analyst Forecasts
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
Frequently Asked Questions
- Is $GNFT stock a Buy, Sell, or Hold?
- What is the price target for $GNFT stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
GNFT Top Shareholders
|
Shareholder
|
Shares Held
|
|---|
Frequently Asked Questions
- Who owns $GNFT stock?
- Who owns the most shares of $GNFT stock?
- What funds own $GNFT stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
GNFT Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view GNFT Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More